

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hiroshi Kawabata et al.

Serial No: 09/358,755

Filed: July 22, 1999

For: Nucleic Acid Encoding Transferrin
Receptor-Like Proteins and Products
Related Thereto

Art Unit: 1644

Examiner: J. Murphy



RECEIVED
APR - 7 2000
TC 1600 MAIL ROOM

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Small entity status of this application under 37 C.F.R. §§ 1.9 & 1.27 has been established by a verified statement previously submitted.
- ☐ A verified statement to establish small entity status under 37 C.F.R. §§ 1.9 & 1.27 is enclosed.
- ☐ A certified copy of ___ Patent Application No. ___ filed ___ from which priority is claimed under 35 U.S.C. § 119 is enclosed.
- ☒ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT		(Col. 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA*	LG/SM \$ ENTITY FEE	ADD'L FEE DUE
TOTAL CLAIMS FEE	23	-	23 **	0	LG=\$18 SM=\$9	\$ 0
INDEPENDENT CLAIMS FEE	4	-	4 ***	0	LG=\$78 SM=\$39	\$ 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIMS					LARGE ENTITY FEE = \$260 SMALL ENTITY FEE = \$130	\$ 0
TOTAL						\$ 0

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box on Col. 1 of a prior amendment or the number of claims originally filed.

- ☐ A check in the amount of \$ 0 to cover the additional claims fee is enclosed. A copy of this sheet is enclosed.
- ☒ A check in the amount of \$ 55 to cover the extension fee is enclosed. A copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiencies of fees associated with this communication or credit any overpayment to Deposit Account No. 12-1820. A copy of this sheet is enclosed.
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17

Respectfully submitted,

LOEB & LOEB LLP

By: Wei-Ning Yang
Registration No. 38,690
Attorney for Applicant(s)

Date: March 30, 2000

10100 Santa Monica Blvd., 22nd Floor
Los Angeles, California 90067-4164
Telephone: 310-282-2000
Facsimile: 310-282-2192CC254270.1
008708D7024
03/29/2000 iy

PATENT
008708-D7024

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hiroshi Kawabata et al.


Serial No: 09/358,755

Filed: July 22, 1999

For: Nucleic Acid Encoding Transferrin
Receptor-Like Proteins and Products
Related Thereto

Art Unit: 1644

Examiner: J. Murphy



I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington D.C. 20231, on

03/30/2000

Date of Deposit

Wei-Ning Yang

Name

Signature

03/30/2000
Date

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sirs:

In response to the Office Action dated February 16, 2000, in connection with the above-identified application, please enter and consider the following remarks.

REMARKS

Claims 1-11 and 19 are in the case.

The Examiner has required restriction to one of the following four groups of the claimed invention:

- I. Claims 1-11 and 19, drawn to nucleic acid, an expression vector, a host cell;
- II. Claims 12-15, drawn to TfR2 polypeptide;
- III. Claims 16-18 and 20, drawn to an antibody; and
- IV. Claims 21-23, drawn to a method of detecting the presence of TfR2 polypeptide.

In response to the Examiner's election requirement, the applicants hereby elect Group I, claims 1-11 and 19, reserving the right to file divisional applications directed to non-elected Groups II-IV, claims 12-18 and 20-23.